Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

Attard, 2016, Prostate cancer, Lancet, 387, 70, 10.1016/S0140-6736(14)61947-4 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Carver, 2011, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell, 19, 575, 10.1016/j.ccr.2011.04.008 Yoshimoto, 2007, FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome, Br J Cancer, 97, 678, 10.1038/sj.bjc.6603924 McCall, 2008, Is PTEN loss associated with clinical outcome measures in human prostate cancer?, Br J Cancer, 99, 1296, 10.1038/sj.bjc.6604680 Reid, 2010, Molecular characterisation of ERG. ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer, Br J Cancer, 102, 678, 10.1038/sj.bjc.6605554 Leinonen, 2013, Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer, Cancer Epidemiol Biomarkers Prev, 22, 2333, 10.1158/1055-9965.EPI-13-0333-T Ferraldeschi, 2015, PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate, Eur Urol, 67, 795, 10.1016/j.eururo.2014.10.027 De Bono, 2016, Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study), J Clin Oncol, 34, 5017, 10.1200/JCO.2016.34.15_suppl.5017 Kolinsky, 2017, A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC, J Clin Oncol, 35, 135, 10.1200/JCO.2017.35.6_suppl.135 Reid, 2012, Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer, Mod Pathol, 25, 902, 10.1038/modpathol.2011.207 Sandhu, 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial, Lancet Oncol, 14, 882, 10.1016/S1470-2045(13)70240-7 Sangale, 2011, A robust immunohistochemical assay for detecting PTEN expression in human tumors, Appl Immunohistochem Mol Morphol, 19, 173, 10.1097/PAI.0b013e3181f1da13 Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Wang, 2008, Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival, Oncogene, 27, 7106, 10.1038/onc.2008.318 Maddika, 2011, WWP2 is an E3 ubiquitin ligase for PTEN, Nat Cell Biol, 13, 728, 10.1038/ncb2240 Mulholland, 2011, Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth, Cancer Cell, 19, 792, 10.1016/j.ccr.2011.05.006 Hodgson, 2011, Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer, Cancer Res, 71, 572, 10.1158/0008-5472.CAN-10-2314 Antonarakis, 2012, An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy, Cancer, 118, 6063, 10.1002/cncr.27689 Demichelis, 2009, Distinct genomic aberrations associated with ERG rearranged prostate cancer, Genes Chromosomes Cancer, 48, 366, 10.1002/gcc.20647 Krohn, 2014, Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer, Mod Pathol, 27, 1612, 10.1038/modpathol.2014.70 Attard, 2008, Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer, Oncogene, 27, 253, 10.1038/sj.onc.1210640 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Saramaki, 2008, TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis, Clin Cancer Res, 14, 3395, 10.1158/1078-0432.CCR-07-2051 Wang, 2006, Expression of variant TMPRSS/ERG fusion messenger RNAs is associated with aggressive prostate cancer, Cancer Res, 66, 8347, 10.1158/0008-5472.CAN-06-1966 Demichelis, 2007, TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort, Oncogene, 26, 4596, 10.1038/sj.onc.1210237 Pettersson, 2012, The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis, Cancer Epidemiol Biomarkers Prev, 21, 1497, 10.1158/1055-9965.EPI-12-0042 Reig, 2016, TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer, Eur Urol, 70, 709, 10.1016/j.eururo.2016.02.034